Cipher Pharmaceuticals Stock Today
| CPH Stock | CAD 18.25 -1.49 -7.55% |
Performance 0High 10 · Moderate | Odds Of Distress HighLow 10 · Low |
Cipher Pharmaceuticals continues trading at C$18.25, reflecting a 7.55% decrease for the day with an intraday range between C$18.0 and C$19.53. Based on quantitative solvency metrics, Cipher Pharmaceuticals reflects a relatively small probability of financial distress. Measured over 90 trading days, Cipher Pharmaceuticals has demonstrated strong risk-adjusted performance. The performance scores are based on the time frame from February 10, 2026 to May 11, 2026. Learn more.
Related SymbolsLess Correlated Symbols Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cipher Pharmaceuticals (CPH) is listed on Toronto Exchange in Canada. CPH operates in the Health Care industry (Pharmaceuticals sector). Cipher Pharmaceuticals is currently valued at CAD 499.05 million by market capitalization, putting the company in the small-cap cohort across health care companies. Related scale indicators include operating in the Health Care industry, enterprise value near CAD 490.88 million, and about 25.28 million shares outstanding. CPH has 69,664 shares sold short (1.93 days to cover). With a net margin of 60.6%, the company retains a relatively high share of revenue as profit. Cipher Pharmaceuticals is an operator in the health care segment where revenue is driven by core operating activity and end-market demand. CPH reported revenue of $51.33 million. Net Income was $27.81 million with profit before overhead, payroll, taxes, and interest of $41.58 million. Cipher Pharmaceuticals financial stability analysis Investment highlights for Cipher Pharmaceuticals are designed to surface the signals most likely to affect valuation, volatility, and portfolio fit. At small-cap scale, institutional coverage and secondary-market liquidity are typically well established.
Ownership Allocation Cipher Pharmaceuticals holds a notable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it may be worth considering to analyze if each of these insiders have been buying or selling the stock in recent months.
Check Cipher Ownership DetailsStock Notable Updates
| Legal Name | Cipher Pharmaceuticals Inc |
| Interim CEO & Chairman of the Board | Craig Mull |
| President | Bryan Jacobs |
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers - Specialty & Generic, Healthcare, (View all Sectors) |
Common Risk Profiles
Cipher Pharmaceuticals' alpha and beta are important CAPM metrics for assessing risk-adjusted returns. Standard measures of volatility play an equally important role in completing the risk assessment. Cross-border risk factors may cause Cipher Pharmaceuticals' volatility to diverge from what alpha and beta alone suggest.
| Mean Deviation | 2.11 | |||
| Semi Deviation | 1.86 | |||
| Standard Deviation | 3.33 | |||
| Variance | 11.1 |
Cipher Pharmaceuticals Against Markets
| GSPTXDV | 0.21 | ||||
| CPH | 7.55 |
| Competition | Compare Correlations |
Investor Insights and Alerts
| Cipher Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company has C$5.49 million in debt which may indicate that it relies heavily on debt financing | |
| About 42.0% of CPH shares are held by company insiders |
Market Capitalization
Cipher Pharmaceuticals is currently valued at CAD 499.05 million by market capitalization, putting the company in the small-cap cohort across health care companies. Related scale indicators include operating in the Health Care industry, enterprise value near CAD 490.88 million, and about 25.28 million shares outstanding.Profitability
Profitability analysis for Cipher Pharmaceuticals focuses on how well revenue converts into operating income, net income, and free cash flow. The best read combines margin history with balance-sheet strength and pricing power under softer demand. CPH has Profit Margin (PM) of 61.0%. Similarly, it shows Operating Margin (OM) of 45.0%.Technical Drivers
As of the 11th of May 2026, Cipher Pharmaceuticals lists a market price of 18.25 per share. Market-based metrics show Downside Deviation of 2.09, risk adjusted performance of 0.1285, and Mean Deviation of 2.11. Structured modeling of historical data supports trend assessment. Current readings are analyzed relative to broader market benchmarks.Price Movement Analysis - Bollinger Bands
Transformation |
This analysis covers sixty-one data points across the selected time horizon. The Inverse Tangent (Arctangent) transformation applies the arctangent function to Cipher Pharmaceuticals's price series, compressing large price values into a bounded range. This can normalize extreme price movements and reveal underlying directional shifts.
Outstanding Bonds
Corporate bonds issued by Cipher Pharmaceuticals matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. Longer-dated obligations can improve financing stability, but they also leave investors more exposed if the underlying business weakens before the debt matures.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley Jul Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Predictive Daily Indicators
Intraday indicators for Cipher Pharmaceuticals suit investors who need a shorter decision cycle and tighter control over timing. For most traders, the benefit is faster feedback on momentum, which sharpens both entries and exits.
Forecast Models
A forecast for Cipher Pharmaceuticals starts with historical data. Prices often signal trend and momentum shifts before fundamentals catch up. Forecast models complement fundamental research by showing where price behavior supports or contradicts the thesis.Stock Overview, Methodology & Data Sources
Cipher Pharmaceuticals operates as a specialty pharmaceutical company in Canada. The company was founded in 2000 and is headquartered in Oakville, Canada. Headquarters are in 5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9. Latest reported figures include market cap 499.05 million, P/E 21.55, P/B 2.76. As a small-cap equity, Cipher Pharmaceuticals is evaluated across valuation, solvency, and efficiency signals. Fundamentals lead the analysis, with market-implied risk context alongside. Lower liquidity environments can sometimes affect short-term price stability.
Methodology
Unless otherwise specified, financial data for Cipher Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cipher (CA:CPH) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cipher Pharmaceuticals may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board
Be Your Own Money Manager
A disciplined portfolio workflow around Cipher Pharmaceuticals tests whether the position strengthens diversification, return efficiency, and aggregate portfolio fit. When applied, optimization turns position sizing and rebalancing into measurable decisions rather than guesswork.
Did You Try This?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Cipher Pharmaceuticals Corporate Executives
Governance review matters for Cipher Pharmaceuticals because boards and executives shape oversight, strategic discipline, and how shareholder interests are represented. A disciplined governance review can reveal strengths or weaknesses that may not be obvious in financial ratios alone.